News and Press Releases

Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development

Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...

Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024

Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET

Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report

24 June 2024 -- Washington, DC -- Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 24, 2024

730 15th Street NW Washington, DC 20005

New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials

Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024

East Lyme, Connecticut, US

Celonic Inaugurates “Next Generation” Biologics Development Centre (BDC) and Pilot Plant in Basel, Switzerland

The Celonic Group, a “Pure Play” Biologics contract development and manufacturing organisation (CDMO), expands process development and optimisation services in Basel Investment builds on “Next Generation” bioprocessing capability and pilot...

Category: BioManufacturing, Pharmaceutical
Posted: June 18, 2024

Eulerstrasse 55 CH - 4051 Basel

China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData

14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...

Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData

Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...

Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

Bold initiative to boost the capacity of research sites enters Beta testing and piloting 12 June 2024 -- North Carolina, US -- IQVIA today announced the launch of One Home...

Category: Clinical Trials, Drug Discovery, Other
Posted: June 12, 2024

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...

Category: Biotechnology, Clinical Trials
Posted: June 12, 2024

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024

Medicon Village, 223 81 Lund, Sweden

CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange

11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024

Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands

Freudenberg Medical Expands Coatings Business with New Production Facility

Investment of more than $50m to meet growing global demand for drug and hydrophilic coatings for medical devices and components Manufacturing footprint tripled with new 130,000sqft facility in the Aachen...

Category: Manufacturing and Packing, Other, Pharmaceutical
Posted: June 11, 2024

Freudenberg Medical Europe GmbH Liebigstraße 2-8 67661 Kaiserslautern Germany

Vetter announces plans to expand its capacity in the US and Germany

Leading globally operating CDMO outlines location and design of new manufacturing sites to meet increasing customer demands Vetter Advisory Board decides on strategic path forward for further independent and sustainable...

Category: Manufacturing and Packing, Other, Pharmaceutical
Posted: June 6, 2024

Schützenstrasse 87, 88212 Ravensburg

Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

2400 Broadway Santa Monica, CA 90404

TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG